NCT02153281CompletedNot Applicable
Neuroimaging MAO-B in Medication Free and Treatment Resistant Major Depressive Disorder Using Novel MAO-B Tracer
Centre for Addiction and Mental Health2 sites in 1 country8 target enrollmentStarted: June 2014Last updated:
Conditions
Interventions
Trial Snapshot
- Phase
- Not Applicable
- Status
- Completed
- Enrollment
- 8
- Locations
- 2
- Primary Endpoint
- MAO-B VT levels measured with PET in MDE secondary to MDD
Study Overview
Brief Summary
The purpose of this study is to determine if monoamine oxidase B (MAO-B) total distribution volume (VT), after phenelzine treatment and if so to what extent.
Detailed Description
Subjects will receive a PET and MRI scan before and after treatment with phenelzine.
Study Design
- Study Type
- Interventional
- Allocation
- Na
- Intervention Model
- Single Group
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to 80 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •18-80 years of age
- •good physical health
- •Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) diagnosis of current major depressive episode (MDE)
- •DSM-IV diagnosis of major depressive disorder (MDD) verified by SCID for DSM-IV and a psychiatric consultation
- •greater than 17 on the 17 item HDRS (Hamilton Depression Rating Scale).
- •history of non-response to several different antidepressant classes
Exclusion Criteria
- •herbal, drug or medication use (that affect CNS function)
- •suicide attempts
- •drug or medication use within eight weeks (+5 half lives of medication)
- •history of substance abuse or any neurotoxin use
- •history of psychotic symptoms
- •history of central nervous system (CNS) medical illness
- •current substance abuse
- •test positive on pregnancy test (for women)
Arms & Interventions
Phenelzine treatment
Experimental
Subjects will undergo a PET and MRI scan before and after the treatment.
Intervention: phenelzine treatment (Other)
Outcomes
Primary Outcomes
MAO-B VT levels measured with PET in MDE secondary to MDD
Time Frame: 8 weeks
Secondary Outcomes
No secondary outcomes reported
Investigators
Jeff Meyer
Head Neurochemical Imaging in Mood Disorders
Centre for Addiction and Mental Health
Study Sites (2)
Loading locations...
Similar Trials
Recruiting
Not Applicable
Study on monoamine oxidase B (MAO-B) distribution differences associated with MAO-B inhibitors and smoking in Parkinson's diseaseParkinson's disease (PD)JPRN-UMIN000049442Cyclotron and Radioisotope Center, Tohoku University57
Completed
Phase 1
A Study of RO4602522 in Patients With Alzheimer Disease and in Healthy VolunteersHealthy Volunteer, Alzheimer's DiseaseNCT01701089Hoffmann-La Roche17
Active, not recruiting
Not Applicable
Assessment of Inhibition of Brain MAO-B by EVT 301 after Repeated Dosing to Steady-state in Patients with Alzheimer’s Disease and in Elderly Control Subjects - Assessment of Inhibition of Brain MAO-B by EVT 301 after Repeated Dosing to Steady-state in PatientsSubjects with probable Alzheimer's Disease and healthy voulunteersEUCTR2006-001261-42-FIEvotec NeuroSciences GmbH
Completed
Not Applicable
The investigation of changes in brain monoamine oxidase-B and their relation to pathologies in mild cognitive impairmentMild cognitive impairment, Healthy volunteerJPRN-UMIN000043458ational Institutes for Quantum and Radiological Science and Technology30
Completed
Not Applicable
MAO-B Occupancy in Depressed PatientsTreatment Resistant DepressionMajor Depressive DisorderNCT04841798Centre for Addiction and Mental Health50